Drug Profile

QRX 003

Alternative Names: QRX-003

Latest Information Update: 28 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Quoin Pharmaceuticals
Class Anti-inflammatories; Skin disorder therapies; Small molecules
Mechanism of Action Serine protease inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Netherton Syndrome
New Molecular Entity Yes

Highest Development Phases

Phase II/III Netherton Syndrome
Clinical Phase Unknown Peeling skin syndrome
No development reported Palmoplantar keratoderma

Most Recent Events

28 Dec 2025 No recent reports of development identified for preclinical development in Palmoplantar keratoderma in USA (Topical, Lotion)
28 Oct 2025 Clinical trials in Netherton-Syndrome (In children) in Austria (Topical)
28 Oct 2025 Efficacy data from a clinical trial in Netherton syndrome released by Quoin Pharmaceuticals

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com